Valuation: Ironwood Pharmaceuticals, Inc.

Market Cap 680M 595M 550M 513M 966M 64.28B 988M 6.61B 2.55B 31.71B 2.55B 2.5B 110B P/E 2026 *
3.5x
P/E 2027 * 3.34x
Enterprise Value 680M 595M 550M 513M 966M 64.28B 988M 6.61B 2.55B 31.71B 2.55B 2.5B 110B EV / Sales 2026 *
1.48x
EV / Sales 2027 * 1.42x
Free-Float
96.84%
Yield 2026 *
-
Yield 2027 * -
1 day+2.78%
1 week+11.13%
Current month+18.91%
1 month+18.91%
3 months+31.42%
6 months+32.24%
Current year+25.96%
1 week 3.76
Extreme 3.76
4.36
1 month 3.14
Extreme 3.145
4.36
Current year 2.95
Extreme 2.95
5.78
1 year 0.67
Extreme 0.6701
5.78
3 years 0.53
Extreme 0.5271
15.7
5 years 0.53
Extreme 0.5271
15.7
10 years 0.53
Extreme 0.5271
21.2
Manager TitleAgeSince
Chief Executive Officer 68 12/03/2021
Director of Finance/CFO 44 15/05/2026
Chief Tech/Sci/R&D Officer - 01/04/2024
Director TitleAgeSince
Director/Board Member 68 04/06/2021
Chairman 61 01/04/2019
Director/Board Member 56 01/04/2019
Date Insider Type Main position Quantity % Market Cap.
06-16Free

Chairman

85,052 0.0517%
06-16Free

Director

63,481 0.0386%
06-16Free

Director

63,481 0.0386%
Change 5-day change 1-year change 3-year change Capi.($)
+2.78%+11.13%+491.89%-60.14% 680M
+0.17%+11.54%+62.72%+13.45% 318B
+0.51%+10.08%+33.09%-2.14% 72.22B
+1.39%+10.26%+46.23%+119.41% 8.89B
+2.55%+1.58%+5.46%-5.29% 8.25B
+9.89%+4.71%-0.22%+11.64% 4.23B
+11.33%+17.21%+11.72%+35.38% 3.58B
+11.14%-3.02%-28.76%+33.60% 3.23B
-1.10%+4.22%+47.07%+54.98% 2.72B
+7.38%+13.80%+17.63%-21.31% 2.03B
Average +4.62%+9.14%+68.68%+17.96% 42.36B
Weighted average by Cap. +0.64%+11.93%+54.82%+12.95%

Financials

2026 *2027 *
Net sales 459M 402M 371M 347M 653M 43.44B 668M 4.47B 1.73B 21.43B 1.73B 1.69B 74.41B 478M 419M 387M 361M 680M 45.23B 695M 4.65B 1.8B 22.31B 1.8B 1.76B 77.46B
Net income 188M 165M 152M 142M 267M 17.8B 274M 1.83B 707M 8.78B 707M 691M 30.48B 210M 184M 170M 158M 298M 19.84B 305M 2.04B 788M 9.79B 788M 771M 33.98B
Net Debt - -
Logo Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Employees
100
Date Price Change Volume
29/06/26 $4.245 +2.78% 1,198,575
26/06/26 $4.130 +7.55% 7,108,527
25/06/26 $3.840 -1.79% 1,659,700
24/06/26 $3.910 +1.30% 1,764,481
23/06/26 $3.860 +1.05% 1,444,965
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.130USD
Average target price
6.100USD
Spread / Average Target
+47.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IRWD Stock